Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.

Body weight Among participants continuing on DAPA + ExQW, body weight loss achieved at 24 weeks (−4.5 kg) was sustained at 52 weeks (−5.7 kg), with some additional body weight loss from 24 to 52 weeks (−1.2 kg) that did not reach statistical significance (Table 1 , Figure 2 A).

also in 111,027 other papers